523 related articles for article (PubMed ID: 27388964)
1. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
2. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
3. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
[TBL] [Abstract][Full Text] [Related]
5. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Vázquez R; Licandro SA; Astorgues-Xerri L; Lettera E; Panini N; Romano M; Erba E; Ubezio P; Bello E; Libener R; Orecchia S; Grosso F; Riveiro ME; Cvitkovic E; Bekradda M; D'Incalci M; Frapolli R
Int J Cancer; 2017 Jan; 140(1):197-207. PubMed ID: 27594045
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Berthon C; Raffoux E; Thomas X; Vey N; Gomez-Roca C; Yee K; Taussig DC; Rezai K; Roumier C; Herait P; Kahatt C; Quesnel B; Michallet M; Recher C; Lokiec F; Preudhomme C; Dombret H
Lancet Haematol; 2016 Apr; 3(4):e186-95. PubMed ID: 27063977
[TBL] [Abstract][Full Text] [Related]
7. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F
Oncotarget; 2016 Dec; 7(51):84675-84687. PubMed ID: 27835869
[TBL] [Abstract][Full Text] [Related]
8. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
9. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
10. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
[TBL] [Abstract][Full Text] [Related]
13. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
16. The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma.
Gu J; Song S; Han H; Xu H; Fan G; Qian C; Qiu Y; Zhou W; Zhuang W; Li B
Mol Pharm; 2018 Nov; 15(11):5387-5396. PubMed ID: 30339013
[TBL] [Abstract][Full Text] [Related]
17. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Tang Y; Ma J
J Exp Clin Cancer Res; 2018 Oct; 37(1):241. PubMed ID: 30285808
[TBL] [Abstract][Full Text] [Related]
20. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]